Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

ClinicalTrials.gov ID: NCT04305496

Public ClinicalTrials.gov record NCT04305496. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 5, 2026, 6:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment With an Aromatase Inhibitor

Study identification

NCT ID: NCT04305496
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 818 participants

Conditions and interventions

Conditions

Locally Advanced (Inoperable) or Metastatic Breast Cancer

Interventions

Capivasertib Drug
Fulvestrant Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 130 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 15, 2020
Primary completion: May 8, 2023
Completion: Jun 21, 2026
Last update posted: Apr 29, 2026

2020 – 2026

United States locations

U.S. sites: 22
U.S. states: 16
U.S. cities: 22

Facility	City	State	ZIP	Site status
Research Site	Gilbert	Arizona	85234	—
Research Site	Orange	California	92868	—
Research Site	San Francisco	California	94143	—
Research Site	Whittier	California	90603	—
Research Site	Fort Myers	Florida	33905	—
Research Site	Jacksonville	Florida	32224	—
Research Site	Westwood	Kansas	66205	—
Research Site	Baltimore	Maryland	21201	—
Research Site	Boston	Massachusetts	02111-1520	—
Research Site	Rochester	Minnesota	55905	—
Research Site	Kansas City	Missouri	64132	—
Research Site	St Louis	Missouri	63156	—
Research Site	Paramus	New Jersey	07652	—
Research Site	Farmington	New Mexico	87401	—
Research Site	Lake Success	New York	11042	—
Research Site	New York	New York	10011	—
Research Site	Greensboro	North Carolina	27403	—
Research Site	Chattanooga	Tennessee	37404	—
Research Site	Nashville	Tennessee	37211	—
Research Site	Dallas	Texas	75246	—
Research Site	Midlothian	Virginia	23114	—
Research Site	Puyallup	Washington	98373	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 193 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04305496, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 29, 2026 · Synced May 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04305496 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →